Physician profile
Jason Zannis
NPI 1881618411
$3,240.51
in general payments reported to CMS, 2019-2025
23 companies · $34.41 in 2025
The $34.41 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $961 · 2020: $674 · 2021: $544 · 2022: $380 · 2023: $648 · 2025: $34.41.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $654.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $549.82 | 2019-2023 | Farxiga, Breztri |
| Novo Nordisk INC | $549.48 | 2019-2023 | Rybelsus, Ozempic |
| Kvk-Tech, INC. | $271.32 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $261.37 | 2019-2023 | Xifaxan, Trulance |
| Lilly USA, LLC | $213.69 | 2020-2023 | Mounjaro |
| Abbott Laboratories | $83.84 | 2022-2023 | Freestyle Libre 2 |
| Idorsia Pharmaceuticals US INC | $79.80 | 2023 | Quviviq |
| Emd Serono, INC. | $77.75 | 2019 | |
| Janssen Pharmaceuticals, INC | $75.68 | 2019-2021 | |
| Pfizer INC. | $62.44 | 2019-2023 | |
| Abbvie INC. | $57.27 | 2023 | Vraylar |
| Glaxosmithkline, LLC. | $56.77 | 2019-2023 | Trelegy Ellipta |
| Corium, LLC | $35.70 | 2023 | Azstarys |
| Jazz Pharmaceuticals INC. | $34.69 | 2021 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Minimed, INC. | $33.67 | 2019-2020 | |
| Medtronic, INC. | $29.90 | 2022 | |
| Allergan, INC. | $27.62 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.19 | 2019 | |
| Lucid Diagnostics INC. | $17.18 | 2023 | |
| Shire North American Group INC | $15.93 | 2019 | |
| Adlon Therapeutics L.P. | $15.00 | 2019 | |
| Currax Pharmaceuticals LLC | $13.46 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Zannis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.